Donald J Johann Jr
Overview
Explore the profile of Donald J Johann Jr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
620
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Gong B, Li D, Kusko R, Novoradovskaya N, Zhang Y, Wang S, et al.
Genome Biol
. 2021 Apr;
22(1):109.
PMID: 33863344
Background: Targeted sequencing using oncopanels requires comprehensive assessments of accuracy and detection sensitivity to ensure analytical validity. By employing reference materials characterized by the U.S. Food and Drug Administration-led SEquence...
12.
Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology
Deveson I, Gong B, Lai K, LoCoco J, Richmond T, Schageman J, et al.
Nat Biotechnol
. 2021 Apr;
39(9):1115-1128.
PMID: 33846644
Circulating tumor DNA (ctDNA) sequencing is being rapidly adopted in precision oncology, but the accuracy, sensitivity and reproducibility of ctDNA assays is poorly understood. Here we report the findings of...
13.
Johann Jr D, Steliga M, Shin I, Yoon D, Arnaoutakis K, Hutchins L, et al.
Exp Biol Med (Maywood)
. 2018 Feb;
243(3):262-271.
PMID: 29405770
Liquid biopsy methodologies, for the purpose of plasma genotyping of cell-free DNA (cfDNA) of solid tumors, are a new class of novel molecular assays. Such assays are rapidly entering the...
14.
Prieto D, Whitely G, Johann Jr D, Blonder J
Methods Mol Biol
. 2018 Jan;
1723:95-110.
PMID: 29344855
The heterogeneity present in solid tumors adds significant difficulty to scientific analysis and improved understanding. Fundamentally, solid tumor formation consists of cancer cells proper along with stromal elements. The burgeoning...
15.
Prieto D, Chan K, Johann Jr D, Ye X, Whitely G, Blonder J
Methods Mol Biol
. 2017 Aug;
1647:71-90.
PMID: 28808996
The discovery of novel drug targets and biomarkers via mass spectrometry (MS)-based proteomic analysis of clinical specimens has proven to be challenging. The wide dynamic range of protein concentration in...
16.
Prieto D, Johann Jr D, Wei B, Ye X, Chan K, Nissley D, et al.
Biomark Med
. 2014 Feb;
8(2):269-86.
PMID: 24521024
The discovery of clinically relevant cancer biomarkers using mass spectrometry (MS)-based proteomics has proven difficult, primarily because of the enormous dynamic range of blood-derived protein concentrations and the fact that...
17.
Chavan S, Bauer M, Peterson E, Heuck C, Johann Jr D
BMC Bioinformatics
. 2013 Nov;
14 Suppl 14:S4.
PMID: 24268045
Background: Transcriptome analysis by microarrays has produced important advances in biomedicine. For instance in multiple myeloma (MM), microarray approaches led to the development of an effective disease subtyping via cluster...
18.
Ye X, Chan K, Prieto D, Luke B, Johann Jr D, Stockwin L, et al.
Methods Mol Biol
. 2013 Apr;
1002:133-49.
PMID: 23625401
Differential (18)O/(16)O stable isotopic labeling that relies on post-digestion (18)O exchange is a simple and efficient method for the relative quantitation of proteins in complex mixtures. This method incorporates two...
19.
Mukherjee S, Rodriguez-Canales J, Hanson J, Emmert-Buck M, Tangrea M, Prieto D, et al.
Methods Mol Biol
. 2013 Apr;
1002:71-83.
PMID: 23625395
The discovery of effective cancer biomarkers is essential for the development of both advanced molecular diagnostics and new therapies/medications. Finding and exploiting useful clinical biomarkers for cancer patients is fundamentally...
20.
Ye X, Luke B, Johann Jr D, Chan K, Prieto D, Ono A, et al.
Methods Mol Biol
. 2012 Jun;
893:223-40.
PMID: 22665304
The role of membrane proteins is critical for regulation of physiologic and pathologic cellular processes. Hence it is not surpassing that membrane proteins make ∼70% of contemporary drug targets. Quantitative...